<DOC>
	<DOCNO>NCT00317122</DOCNO>
	<brief_summary>This study include infant born mother test seronegative human immunodeficiency virus ( HIV ) &amp; hepatitis B surface antigen ( HBsAg ) . The purpose study demonstrate infant receive birth dose hepatitis B vaccine Tritanrix™-HepB/Hib-MenAC vaccine least good Tritanrix™-HepB/Hiberix™ respect immunogenicity hepatitis B antigen .</brief_summary>
	<brief_title>Assess Immune Response Following Primary Vaccination With GSK Biologicals ' Tritanrix™-HepB/Hib-MenAC v Tritanrix™-HepB/Hiberix™ Given 6,10 &amp; 14 Wks Age Infants Who Received Hepatitis B Vaccine Birth</brief_title>
	<detailed_description>Randomized study two group receive one follow vaccination regimen : - GSK Biologicals ' Tritanrix™-HepB/Hib-MenAC - GSK Biologicals ' Tritanrix™-HepB/Hiberix™</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Healthy infant age 7 day +/ 3 day old born mother test seronegative HIV &amp; HBsAg , write informed consent obtain parent , born gestation period 36 42 week . Exclusion criterion : Known exposure diphtheria , tetanus , pertussis , hepatitis B , Haemophilus influenzae type b and/or meningococcal disease since birth . Any confirm suspected immunosuppressive immunodeficient condition , base physical examination . A family history congenital hereditary immunodeficiency . Major congenital defect serious illness . Any neurologic disorder seizure . Acute disease time enrolment . Administration immunoglobulins and/or blood product since birth plan administration study period . A birth dose hepatitis B vaccine give outside frame study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Days</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>